- Home
- MRSN vs SOPH Comparison
MRSN vs SOPH Comparison
Compare MRSN & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- SOPH
- Stock Information
- Founded
- MRSN 2001
- SOPH 2011
- Country
- MRSN United States
- SOPH Switzerland
- Employees
- MRSN N/A
- SOPH N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRSN Health Care
- SOPH Health Care
- Exchange
- MRSN Nasdaq
- SOPH Nasdaq
- Market Cap
- MRSN 230.0M
- SOPH 247.0M
- IPO Year
- MRSN 2017
- SOPH 2021
- Fundamental
- Price
- MRSN $2.21
- SOPH $3.53
- Analyst Decision
- MRSN Buy
- SOPH Strong Buy
- Analyst Count
- MRSN 6
- SOPH 3
- Target Price
- MRSN $6.00
- SOPH $7.00
- AVG Volume (30 Days)
- MRSN 1.1M
- SOPH 29.6K
- Earning Date
- MRSN 11-13-2024
- SOPH 11-05-2024
- Dividend Yield
- MRSN N/A
- SOPH N/A
- EPS Growth
- MRSN N/A
- SOPH N/A
- EPS
- MRSN N/A
- SOPH N/A
- Revenue
- MRSN $34,837,000.00
- SOPH $64,488,000.00
- Revenue This Year
- MRSN N/A
- SOPH $7.34
- Revenue Next Year
- MRSN $7.15
- SOPH $20.25
- P/E Ratio
- MRSN N/A
- SOPH N/A
- Revenue Growth
- MRSN N/A
- SOPH 9.85
- 52 Week Low
- MRSN $1.22
- SOPH $2.70
- 52 Week High
- MRSN $6.28
- SOPH $7.37
- Technical
- Relative Strength Index (RSI)
- MRSN 51.26
- SOPH 48.03
- Support Level
- MRSN $2.12
- SOPH $3.40
- Resistance Level
- MRSN $2.83
- SOPH $3.99
- Average True Range (ATR)
- MRSN 0.24
- SOPH 0.30
- MACD
- MRSN 0.03
- SOPH 0.02
- Stochastic Oscillator
- MRSN 39.81
- SOPH 37.84
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.